<p>有些人認為波動性，而不是債務，是投資者思考風險的最佳方式，但沃倫·巴菲特曾著名地説過：“波動性遠非風險的同義詞。” 因此，聰明的錢知道，債務——通常與破產相關聯——在評估一家公司風險時是一個非常重要的因素。我們注意到 <strong>ZIM Laboratories Limited</strong> (NSE:ZIMLAB) 的資產負債表上確實有債務。但這對股東來説是個問題嗎？</p>
<p>這項技術可能會取代計算機：發現 20 只正在努力使量子計算成為現實的股票。</p>
<h2>債務帶來什麼風險？</h2>
<p>債務在企業能夠償還時是有幫助的，無論是通過新資本還是自由現金流。如果情況變得非常糟糕，貸款方可能會控制企業。然而，更常見（但仍然痛苦）的情況是，公司不得不以低價籌集新的股本，從而永久性地稀釋股東的權益。話雖如此，最常見的情況是公司合理管理其債務，並使其對自身有利。考慮公司債務水平的第一步是將其現金和債務一起考慮。</p>
<h2>ZIM Laboratories 的債務有多少？</h2>
<p>正如您在下面看到的，截至 2025 年 9 月底，ZIM Laboratories 的債務為 ₹1.17b，較一年前的 ₹973.5m 增加。點擊圖片以獲取更多詳細信息。另一方面，它有 ₹46.3m 的現金，導致淨債務約為 ₹1.13b。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/58281653-debt-equity-history-analysis-1-dark-2/1768522290441?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/58281653-debt-equity-history-analysis-1-dark-2/1768522290441"/></p>
<p>NSEI:ZIMLAB 債務與股本歷史 2026 年 1 月 16 日</p>
<h2>ZIM Laboratories 的資產負債表健康嗎？</h2>
<p>我們可以從最新的資產負債表中看到，ZIM Laboratories 有 ₹1.60b 的負債在一年內到期，以及 ₹585.5m 的負債在此之後到期。抵消這些義務，它有 ₹46.3m 的現金以及價值 ₹1.02b 的應收賬款將在 12 個月內到期。因此，它的負債總額比其現金和短期應收賬款的總和多出 ₹1.12b。</p>
<p>這個赤字並不算太糟，因為 ZIM Laboratories 的市值為 ₹3.69b，因此如果需要，可能能夠籌集足夠的資本來鞏固其資產負債表。然而，仔細觀察其償還債務的能力仍然是值得的。</p>
<p>查看我們對 ZIM Laboratories 的最新分析</p>
<p>我們通過查看公司的淨債務與其息税折舊攤銷前利潤（EBITDA）的比率，以及計算其息税前利潤（EBIT）覆蓋利息支出的能力（利息覆蓋率），來衡量公司的債務負擔相對於其盈利能力的情況。這種方法的優點在於，我們考慮了債務的絕對數量（淨債務與 EBITDA 的比率）以及與該債務相關的實際利息支出（其利息覆蓋率）。</p>
<p>雖然我們不會擔心 ZIM Laboratories 的淨債務與 EBITDA 比率為 3.5，但我們認為其超低的利息覆蓋率為 1.7 倍是高槓杆的跡象。顯然，借款成本最近對股東的回報產生了負面影響。更糟的是，ZIM Laboratories 的 EBIT 在過去一年下降了 37%。如果盈利長期保持這種趨勢，它幾乎沒有機會償還這筆債務。在分析債務時，資產負債表顯然是重點。但您不能完全孤立地看待債務；因為 ZIM Laboratories 需要盈利來償還這筆債務。因此，如果您想了解更多關於其盈利的信息，查看其長期盈利趨勢的圖表可能是值得的。</p>
<p>最後，一家公司只能用現金償還債務，而不是會計利潤。因此，我們顯然需要查看 EBIT 是否帶來了相應的自由現金流。在過去三年中，ZIM Laboratories 消耗了大量現金。雖然這可能是由於增長支出的結果，但這確實使債務變得更加風險。</p>
<h2>我們的看法</h2>
<p>乍一看，ZIM Laboratories 將 EBIT 轉換為自由現金流讓我們對該股票持謹慎態度，其 EBIT 增長率也沒有比一年中最繁忙的夜晚唯一空餐廳更具吸引力。話雖如此，其處理總負債的能力並不是一個大問題。總體而言，我們認為 ZIM Laboratories 的資產負債表對業務來説確實是一個風險。因此，我們對該股票持相當謹慎的態度，並認為股東應該密切關注其流動性。在分析債務水平時，資產負債表顯然是一個起點。但最終，每家公司都可能存在資產負債表之外的風險。<strong>我們已經識別出 ZIM Laboratories 的 4 個警告信號</strong>（至少有 1 個可能是嚴重的），理解這些信號應該是您投資過程的一部分。</p>
<p>歸根結底，通常更好的是關注沒有淨債務的公司。您可以訪問我們特別列出的這些公司（所有公司都有盈利增長的記錄）。這是免費的。</p>

<p>ZIM Laboratories (NSE:ZIMLAB) 的淨債務為 11.3 億印度盧比，而市場價值為 36.9 億印度盧比，這引發了對其財務健康的擔憂。公司的負債總額為 11.2 億印度盧比，超過了現金和應收賬款，公司的債務管理能力受到審視。其淨債務與 EBITDA 的比率為 3.5，但 1.7 的低利息覆蓋率表明槓桿率較高。此外，過去一年 EBIT 下降了 37%，進一步引發了對其償債能力的擔憂。總體而言，資產負債表存在風險，促使股東對流動性和債務管理保持謹慎</p>

<p>Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. We note that <strong>ZIM Laboratories Limited</strong> (NSE:ZIMLAB) does have debt on its balance sheet. But is this debt a concern to shareholders?</p>
<div class="lb-trans"><p>有些人認為波動性，而不是債務，是投資者思考風險的最佳方式，但沃倫·巴菲特曾著名地説過：“波動性遠非風險的同義詞。” 因此，聰明的錢知道，債務——通常與破產相關聯——在評估一家公司風險時是一個非常重要的因素。我們注意到 <strong>ZIM Laboratories Limited</strong> (NSE:ZIMLAB) 的資產負債表上確實有債務。但這對股東來説是個問題嗎？</p>
</div><p>This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.</p>
<div class="lb-trans"><p>這項技術可能會取代計算機：發現 20 只正在努力使量子計算成為現實的股票。</p>
</div><h2>What Risk Does Debt Bring?</h2>
<div class="lb-trans"><h2>債務帶來什麼風險？</h2>
</div><p>Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. If things get really bad, the lenders can take control of the business. However, a more common (but still painful) scenario is that it has to raise new equity capital at a low price, thus permanently diluting shareholders. Having said that, the most common situation is where a company manages its debt reasonably well - and to its own advantage. The first step when considering a company's debt levels is to consider its cash and debt together.</p>
<div class="lb-trans"><p>債務在企業能夠償還時是有幫助的，無論是通過新資本還是自由現金流。如果情況變得非常糟糕，貸款方可能會控制企業。然而，更常見（但仍然痛苦）的情況是，公司不得不以低價籌集新的股本，從而永久性地稀釋股東的權益。話雖如此，最常見的情況是公司合理管理其債務，並使其對自身有利。考慮公司債務水平的第一步是將其現金和債務一起考慮。</p>
</div><h2>How Much Debt Does ZIM Laboratories Carry?</h2>
<div class="lb-trans"><h2>ZIM Laboratories 的債務有多少？</h2>
</div><p>As you can see below, at the end of September 2025, ZIM Laboratories had ₹1.17b of debt, up from ₹973.5m a year ago. Click the image for more detail. On the flip side, it has ₹46.3m in cash leading to net debt of about ₹1.13b.</p>
<div class="lb-trans"><p>正如您在下面看到的，截至 2025 年 9 月底，ZIM Laboratories 的債務為 ₹1.17b，較一年前的 ₹973.5m 增加。點擊圖片以獲取更多詳細信息。另一方面，它有 ₹46.3m 的現金，導致淨債務約為 ₹1.13b。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/58281653-debt-equity-history-analysis-1-dark-2/1768522290441" alt="" original-src="https://images.simplywall.st/asset/chart/58281653-debt-equity-history-analysis-1-dark-2/1768522290441"/></p>
<p>NSEI:ZIMLAB Debt to Equity History January 16th 2026</p>
<div class="lb-trans"><p>NSEI:ZIMLAB 債務與股本歷史 2026 年 1 月 16 日</p>
</div><h2>How Healthy Is ZIM Laboratories' Balance Sheet?</h2>
<div class="lb-trans"><h2>ZIM Laboratories 的資產負債表健康嗎？</h2>
</div><p>We can see from the most recent balance sheet that ZIM Laboratories had liabilities of ₹1.60b falling due within a year, and liabilities of ₹585.5m due beyond that. Offsetting these obligations, it had cash of ₹46.3m as well as receivables valued at ₹1.02b due within 12 months. So its liabilities total ₹1.12b more than the combination of its cash and short-term receivables.</p>
<div class="lb-trans"><p>我們可以從最新的資產負債表中看到，ZIM Laboratories 有 ₹1.60b 的負債在一年內到期，以及 ₹585.5m 的負債在此之後到期。抵消這些義務，它有 ₹46.3m 的現金以及價值 ₹1.02b 的應收賬款將在 12 個月內到期。因此，它的負債總額比其現金和短期應收賬款的總和多出 ₹1.12b。</p>
</div><p>This deficit isn't so bad because ZIM Laboratories is worth ₹3.69b, and thus could probably raise enough capital to shore up its balance sheet, if the need arose. However, it is still worthwhile taking a close look at its ability to pay off debt.</p>
<div class="lb-trans"><p>這個赤字並不算太糟，因為 ZIM Laboratories 的市值為 ₹3.69b，因此如果需要，可能能夠籌集足夠的資本來鞏固其資產負債表。然而，仔細觀察其償還債務的能力仍然是值得的。</p>
</div><p>View our latest analysis for ZIM Laboratories</p>
<div class="lb-trans"><p>查看我們對 ZIM Laboratories 的最新分析</p>
</div><p>We measure a company's debt load relative to its earnings power by looking at its net debt divided by its earnings before interest, tax, depreciation, and amortization (EBITDA) and by calculating how easily its earnings before interest and tax (EBIT) cover its interest expense (interest cover). The advantage of this approach is that we take into account both the absolute quantum of debt (with net debt to EBITDA) and the actual interest expenses associated with that debt (with its interest cover ratio).</p>
<div class="lb-trans"><p>我們通過查看公司的淨債務與其息税折舊攤銷前利潤（EBITDA）的比率，以及計算其息税前利潤（EBIT）覆蓋利息支出的能力（利息覆蓋率），來衡量公司的債務負擔相對於其盈利能力的情況。這種方法的優點在於，我們考慮了債務的絕對數量（淨債務與 EBITDA 的比率）以及與該債務相關的實際利息支出（其利息覆蓋率）。</p>
</div><p>While we wouldn't worry about ZIM Laboratories's net debt to EBITDA ratio of 3.5, we think its super-low interest cover of 1.7 times is a sign of high leverage. It seems clear that the cost of borrowing money is negatively impacting returns for shareholders, of late. Worse, ZIM Laboratories's EBIT was down 37% over the last year. If earnings keep going like that over the long term, it has a snowball's chance in hell of paying off that debt. The balance sheet is clearly the area to focus on when you are analysing debt. But you can't view debt in total isolation; since ZIM Laboratories will need earnings to service that debt. So if you're keen to discover more about its earnings, it might be worth checking out this graph of its long term earnings trend.</p>
<div class="lb-trans"><p>雖然我們不會擔心 ZIM Laboratories 的淨債務與 EBITDA 比率為 3.5，但我們認為其超低的利息覆蓋率為 1.7 倍是高槓杆的跡象。顯然，借款成本最近對股東的回報產生了負面影響。更糟的是，ZIM Laboratories 的 EBIT 在過去一年下降了 37%。如果盈利長期保持這種趨勢，它幾乎沒有機會償還這筆債務。在分析債務時，資產負債表顯然是重點。但您不能完全孤立地看待債務；因為 ZIM Laboratories 需要盈利來償還這筆債務。因此，如果您想了解更多關於其盈利的信息，查看其長期盈利趨勢的圖表可能是值得的。</p>
</div><p>Finally, a company can only pay off debt with cold hard cash, not accounting profits. So we clearly need to look at whether that EBIT is leading to corresponding free cash flow. During the last three years, ZIM Laboratories burned a lot of cash. While that may be a result of expenditure for growth, it does make the debt far more risky.</p>
<div class="lb-trans"><p>最後，一家公司只能用現金償還債務，而不是會計利潤。因此，我們顯然需要查看 EBIT 是否帶來了相應的自由現金流。在過去三年中，ZIM Laboratories 消耗了大量現金。雖然這可能是由於增長支出的結果，但這確實使債務變得更加風險。</p>
</div><h2>Our View</h2>
<div class="lb-trans"><h2>我們的看法</h2>
</div><p>On the face of it, ZIM Laboratories's conversion of EBIT to free cash flow left us tentative about the stock, and its EBIT growth rate was no more enticing than the one empty restaurant on the busiest night of the year. Having said that, its ability to handle its total liabilities isn't such a worry. Overall, it seems to us that ZIM Laboratories's balance sheet is really quite a risk to the business. For this reason we're pretty cautious about the stock, and we think shareholders should keep a close eye on its liquidity. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately, every company can contain risks that exist outside of the balance sheet. <strong>We've identified 4 warning signs</strong> with ZIM Laboratories (at least 1 which is potentially serious) , and understanding them should be part of your investment process.</p>
<div class="lb-trans"><p>乍一看，ZIM Laboratories 將 EBIT 轉換為自由現金流讓我們對該股票持謹慎態度，其 EBIT 增長率也沒有比一年中最繁忙的夜晚唯一空餐廳更具吸引力。話雖如此，其處理總負債的能力並不是一個大問題。總體而言，我們認為 ZIM Laboratories 的資產負債表對業務來説確實是一個風險。因此，我們對該股票持相當謹慎的態度，並認為股東應該密切關注其流動性。在分析債務水平時，資產負債表顯然是一個起點。但最終，每家公司都可能存在資產負債表之外的風險。<strong>我們已經識別出 ZIM Laboratories 的 4 個警告信號</strong>（至少有 1 個可能是嚴重的），理解這些信號應該是您投資過程的一部分。</p>
</div><p>At the end of the day, it's often better to focus on companies that are free from net debt. You can access our special list of such companies (all with a track record of profit growth). It's free.</p>
<div class="lb-trans"><p>歸根結底，通常更好的是關注沒有淨債務的公司。您可以訪問我們特別列出的這些公司（所有公司都有盈利增長的記錄）。這是免費的。</p>
</div>

ZIM Laboratories（NSE:ZIMLAB）是否為一項高風險投資？